Celularity Inc

GX Acquisition Corp. II, trading under the ticker GXGX, was a blank-check company sponsored by GX Sponsor II LLC that completed its initial public offering in 2020, targeting opportunities in the healthcare and biotechnology sector. The SPAC filed an 8-K on July 15, 2021, corresponding to the closing of its business combination with Celularity Inc., a clinical-stage biotechnology company focused on placental-derived cellular medicines and allogeneic cell therapies. Following the merger, Celularity began trading as a public company, and GXGX transitioned to a completed de-SPAC status. The transaction brought Celularity's regenerative and immuno-oncology pipeline to public markets. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on GXGX and hundreds of other SPACs.